Healthcare professionals&#39; and consumers&#39; knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review

Lim, CX; Bozkurt, A; Chen, ZY; Hird, A; Wickens, J; Lazarakis, S; Hussainy, SY; Alexander, M

Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review

Author(s): Lim, CX; Bozkurt, A; Chen, ZY; Hird, A; Wickens, J; Lazarakis, S; Hussainy, SY; Alexander, M;
Details: Publication Year 2023-11-22,Volume 16,Issue #12,Page 2467-2482
Journal Title: Clinical and Translational Science
Publication Type: Review
Abstract: Clinical implementation of pharmacogenomic (PGx)-guided prescribing in oncology lags behind research evidence generation. We aimed to identify healthcare professionals' (HCPs) and consumers' knowledge, attitudes, perspectives, and education needs to inform strategies for implementation of scalable and sustainable oncology PGx programs. Systematic review of original articles indexed in EMBASE, EMCARE, MEDLINE, and PsycInfo from January 2012 until June 2022, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and using the Mixed Methods Appraisal Tool. PROSPERO registration number CRD42022352348. Of 1442 identified studies; 23 met inclusion criteria with 87% assessed high quality. Of these, 52% reported on HCPs, 35% on consumers, and 13% on both HCPs and consumers. Most were conducted in the United States (70%) and included multiple cancer types (74%). Across studies, HCPs and consumers mostly perceived value in PGx, however, both groups reported barriers to utilization, including cost, lack of consistent recommendations across guidelines, and limited knowledge among HCPs; test accuracy, clear testing benefits, and genomic information confidentiality among consumers. HCPs and consumers value and want to engage in PGx strategies in oncology care, however, are inhibited by unmet needs and practice and knowledge gaps. Implementation strategies aimed at addressing these issues may best support increased PGx uptake in oncology practice.
Department(s): Pharmacy
Publisher's Version: https://doi.org/10.1111/cts.13672
Open Access at Publisher's Site: https://doi.org/10.1111/cts.13672
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-12-20 05:40:24

Last Modified: 2023-12-20 06:31:07